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Antibodies are a major component of
specific immune protection against influen-
za and remain the established immune
correlate of protection for influenza vac-
cines. The importance of humoral immu-
nity against influenza infection is further
highlighted by the apparent success of
passive immunotherapy with convalescent
sera during the 1918 Spanish influenza
pandemic, and more recently by anecdotal
reports of treating H5N1 human infection
with convalescent sera [1,2]. Human
monoclonal antibodies to H5N1 viruses
have been generated from immortalized
human memory B cells obtained from
patients who recovered from H5N1 disease
[3] or with combinational antibody library
technologies [4]. Some of these antibodies
have broad H5N1 cross-clade reactivity
[3,4] or cross-subtype reactivity to H1
viruses [4], and are effective in suppressing
H5N1 virus disease in experimentally
infected animals when administered pro-
phylactically or therapeutically [3].
Influenza hemagglutinin (HA), with 16
antigenically distinct subtypes, and neur-
aminidase (NA), with nine antigenically
distinct subtypes, are the major surface
glycoproteins targeted by host antibody
response. Antibodies against HA may
neutralize the virus through blocking viral
attachment to the sialyl receptors on host
cells or through interfering with HA
conformational changes at low pH within
the endosome, thereby preventing fusion
and uncoating of the virus [5–8]. Although
anti-NA antibodies cannot provide a
sterilizing effect in vivo, they have been
shown to reduce viral titers, morbidity,
and viral shedding [9–12]. M2 is a
conserved viral protein abundantly ex-
pressed on the infected cell surface, and
anti-M2 antibodies may provide broad
cross-protection to influenza viruses of
different subtypes (known as heterosubty-
pic immunity) [13].
Although influenza control relies on
eliciting protective humoral immunity
through vaccination, there is insufficient
information on the antibody epitopes on
influenza viruses. Much of the available
information pertains to antibodies gener-
ated from mice rather than humans [14].
Antibody epitopes have been identified
from only five of the 11 viral proteins, and
most of these epitopes are on the viral HA
[14]. Epitope mapping using monoclonal
antibodies and the availability of the 3-
dimensional structure have identified five
antigenic sites in the HA of H3 subtype
[15,16]. Corresponding antigenic sites
have also subsequently been mapped to
H1 and H2 subtypes [17,18]. The anti-
body binding epitopes of the H5 HA
epitopes have been mapped using virus
escape mutants (viral variants that can
escape recognition by the monoclonal
antibodies) and are located exclusively in
areas corresponding to antigenic sites A
and B of H3 HA and the antigenic site Sa
of H1 HA [19,20], at the upper surface of
the HA molecule. Furthermore, differenc-
es between a low-pathogenic strain (A/
Mallard/Pennsylvania/10218/84
[H5N2]) and a recent high-pathogenic
strain (A/Vietnam/1203/04 [H5N1])
have been observed, suggesting the poten-
tial differences in HA conformations even
within the same subtype [19,20].
A New Study on Human
Antibodies Generated in
Response to H5N1
In the current issue of PLoS Medicine,
Hana Golding and coauthors [21] use
whole-genome-fragment phage display li-
braries (see Glossary) expressing fragments
of a clade 1 H5N1 influenza virus (A/
Vietnam/1203/04) and a random peptide
phage display library to define the confor-
mation-dependent epitopes of two neu-
tralizing human monoclonal antibodies,
one with reactivity restricted to clade 1
viruses and the other with capacity for
broader cross-clade protection [3]. They
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Khurana S, Suguitan AL Jr., Rivera Y,
Simmons CP, Lanzavecchia A, et al.
(2009) Antigenic fingerprinting of
H5N1 avian influenza using conva-
lescent sera and monoclonal anti-
bodies reveals potential vaccine
and diagnostic targets. PLoS Med
6(4): e1000049. doi:10.1371/journal.
pmed.1000049
Using whole-genome-fragment pha-
ge display libraries, Hana Golding and
colleagues identify the viral epitopes
recognized by serum antibodies in
humans who have recovered from
infection with H5N1 avian influenza.
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go on to define the H5N1 virus reactive
antibody epitopes recognized in the con-
valescent sera from five patients with
H5N1 disease collected between 54 and
182 days after hospitalization. H5N1-spe-
cific epitopes were identified in HA and
NA surface glycoproteins as well as M2e,
PB1-F2, and others. To differentiate
potential cross-reactive antibody response
elicited by previous exposure to H1N1 or
H3N2 influenza viruses, control sera
obtained from Vietnamese (n=20) and
US (n=10) residents with no known
exposure to H5N1 virus were also ana-
lyzed against the H5N1 whole-genome-
fragment phage display library. Cross-
reactive epitopes were identified in several
H5N1 viral proteins, with strong reactions
to peptides in HA and M1 and PA. This
study provides much-needed information
on the human antibody repertoire gener-
ated in response to H5N1 influenza virus
infection, and these findings open up new
avenues of research.
New Avenues of Research
Arising from This Study
Further work is required to define
which of these antibody epitopes elicit
antibodies that protect against H5N1
infection, whether such protection spans
many of the H5N1 clades and subclades,
and whether some of these antibodies
provide protection that might even extend
to other influenza virus subtypes. It is
expected that some of the epitopes in the
HA are targets for the neutralizing anti-
bodies; however, it is also important to
evaluate whether the antibodies targeting
epitopes in NA and M2e may facilitate
clearance of H5N1 infection. The protec-
tive roles for cross-reactive antibodies
targeting NA have been suggested previ-
ously [22]. As the NA epitope identified by
Golding and colleagues is located in
proximity to the enzyme active site, it is
possible that the interacting antibody can
block NA enzymatic activity and thereby
block viral release. Antibodies targeting
M2e have been shown to be effective in
animal models [23], and an M2e vaccine
is currently being evaluated in clinical
trials as an universal vaccine for influenza
because of presumed broad subtype cross-
reactivity induced by such antigens. M2e
has previously been reported as being
weakly immunogenic, and such antibodies
detected after natural influenza infection
are of low titer and of short duration [24].
Golding and colleagues found that four
H5N1 convalescent sera (collected 54–
113 days post-admission) showed strong
M2e antibody titers ($2,500), while the
fifth H5N1 convalescent serum collected
at 182 days post-admission showed a low
antibody titer (of 100). Whether this
reflects the short duration of an M2e
antibody response needs to be established.
Surprisingly, sera from controls with no
exposure to H5N1 virus but with high
antibody titres to seasonal influenza virus-
es had no reactivity to these H5N1 M2e
epitopes.
It would be important to establish
whether these H5N1 M2e epitopes confer
protection against other influenza sub-
types, including seasonal human influenza
viruses. Human H5N1 disease differs from
seasonal influenza in disease pathogenesis
and in the extent of acute lung injury.
Thus we need to understand whether the
differences observed between H5N1 con-
valescent sera and control sera from
persons with high titers to seasonal
influenza virus are the result of differences
in such disease pathology.
Some of the epitopes found to be
reactive with convalescent sera from
H5N1 patients were also found to cross-
react with the control sera from individu-
als with exposure to seasonal influenza
(such as peptide HA-2376-2659). It is
important to explore these epitopes further
to determine if any of them are conserved
across different influenza virus subtypes. It
is interesting to note that others have
recently derived human monoclonal anti-
bodies that neutralize many (though not
all) influenza virus subtypes, and some of
these antibodies provide protection in
experimentally infected mice [25,26].
These monoclonal antibodies appear to
target conserved domains in the HA1/
HA2 stem region and lead to virus
neutralization by inhibiting membrane
fusion [26,27]. Studies are needed to
further elucidate if some of the cross-
reactive HA epitopes found in Golding
and colleagues’ study are also related to
this region. Such information is important
in generating passive antibodies and
vaccines with the capacity to protect
against multiple influenza virus subtypes.
These new insights provide a better
understanding of antibody epitopes of
influenza and are crucial to our efforts to
be better prepared for the next pandemic.
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Glossary
Random peptide phage display library: A technique that can be used to
select peptide ligands binding to a target molecule (peptide, protein [e.g.,
antibody], DNA, or RNA). A library of bacteriophages each expressing a random
peptide (e.g., 12 mers) fused to the bacteriophage surface proteins is generated.
Bacteriophages that specifically bind to the target molecule are purified through
repeated cycles of binding and elution, and the inserts are PCR amplified and
sequenced to deduce the peptide that binds to the target molecule. In the paper
by Golding et al., this strategy was used to identify the viral epitopes (peptide
sequences) recognized by two monoclonal antibodies targeting the H5N1 HA.
This method provides fine mapping of antibody epitope to short peptide
sequence as compared to the whole-genome-fragment phage display libraries
(see below).
Whole-genome-fragment phage display libraries: Instead of using random
peptides, the cDNA corresponding to the whole genome of a 2004 human H5N1
influenza isolate was used to construct the phage display library. In the study by
Golding et al., cDNA of size ranges of 50–200 or 200–1,000 bp was used to
construct the phage display library. Convalescent sera from patients with H5N1
disease were used to probe this phage display library, and the virus epitopes
binding specific antibodies were identified.
Clade 1 H5N1 influenza virus: Phylogenetic analysis of the HA gene of highly
pathogenic avian influenza H5N1 viruses has led to the subdivision of these
viruses into ten virus clades. Phylogenetic trees are like family trees, and a clade of
viruses are a group of viruses that are more closely related genetically. The
different genetic clades of virus are generally, but not invariably, antigenically
distinct, and these differences are relevant in designing vaccines and in assessing
vaccine cross-protection.
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